Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives Consensus Recommendation of “Hold” from Analysts

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has earned an average rating of “Hold” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.6667.

Several equities analysts have commented on LKFT shares. Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings cut Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Royal Bank Of Canada lowered their price objective on Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 11th. Morgan Stanley dropped their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating for the company in a report on Tuesday, August 11th. Finally, Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th.

Lakefront Biotherapeutics American Depositary Shares Stock Down 0.0%

NASDAQ:LKFT opened at $27.52 on Tuesday. The stock’s 50-day simple moving average is $28.67 and its 200 day simple moving average is $29.89. The firm has a market capitalization of $1.81 billion, a PE ratio of -19.52 and a beta of 0.27. Lakefront Biotherapeutics American Depositary Shares has a twelve month low of $25.68 and a twelve month high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.01. The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $7.29 million. On average, analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of hedge funds have recently modified their holdings of the business. Western Standard LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the fourth quarter worth $1,046,000. UBS Group AG raised its position in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% during the fourth quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after acquiring an additional 196,445 shares during the last quarter. National Bank of Canada FI acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter worth approximately $494,000. BNP Paribas Financial Markets lifted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 81.0% in the third quarter. BNP Paribas Financial Markets now owns 11,854 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 5,305 shares during the period. Finally, Geode Capital Management LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at approximately $220,000. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.